Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 31, 2021 | Series A | $30M | 1 | Lyell Immunopharma | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lyell Immunopharma | Yes | Series A |